PK Study of WD-1603 in Healthy Subjects
Phase 1
- Conditions
- Parkinson Disease
- Interventions
- Drug: WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Hong Kong WD Pharmaceutical Co., Limited
- Target Recruit Count
- 8
- Registration Number
- NCT04591535
- Locations
- 🇮🇳
Lambda Therapeutic Research Ltd., Ahmedabad, India
A Single Dose Bioequivalence Study of WD-1602 Versus Pradaxa® in Healthy Subjects Under Fed Condition
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2020-11-02
- Lead Sponsor
- Hong Kong WD Pharmaceutical Co., Limited
- Target Recruit Count
- 20
- Registration Number
- NCT04592822
A Single Oral Dose, Crossover Comparative PK Study of WD-1603 in Healthy Subjects Under Fasting Conditions
- First Posted Date
- 2020-09-18
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- Hong Kong WD Pharmaceutical Co., Limited
- Target Recruit Count
- 8
- Registration Number
- NCT04553978
WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects
Phase 1
- Conditions
- Parkinson Disease
- Interventions
- Drug: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- Hong Kong WD Pharmaceutical Co., Limited
- Target Recruit Count
- 8
- Registration Number
- NCT04513340
- Locations
- 🇮🇳
Lambda Therapeutic Research Ltd., Ahmedabad, India
WD-1603 PK Study in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: carbidopa-levodopa
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2020-02-13
- Lead Sponsor
- Hong Kong WD Pharmaceutical Co., Limited
- Target Recruit Count
- 8
- Registration Number
- NCT03761004
- Locations
- 🇨🇦
INC Research Toronto, Inc., Toronto, Canada
© Copyright 2025. All Rights Reserved by MedPath